ACIU
Closed
Ac Immune Ltd
1.98
-0.05 (-2.46%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.03
Day's Range: 1.65 - 2.08
Send
sign up or login to leave a comment!
When Written:
2.3549
AC Immune Ltd is a Swiss-based biotechnology company that specializes in the discovery and development of innovative treatments for neurodegenerative diseases. The company was founded in 2003 and has since become a leader in the field of protein misfolding and aggregation, which is believed to be a major cause of many neurodegenerative diseases such as Alzheimer's and Parkinson's.
AC Immune uses a proprietary technology platform to develop small molecule drugs, biologics, and vaccines that target misfolded proteins. The company has a diverse pipeline of drug candidates that are currently in various stages of clinical development, including treatments for Alzheimer's disease, Parkinson's disease, and Down syndrome.
AC Immune has partnerships with several leading pharmaceutical companies, including Roche, Genentech, and Eli Lilly, to develop and commercialize its drug candidates. The company is also engaged in research collaborations with academic institutions and other biotech companies to advance its understanding of neurodegenerative diseases and develop new treatments.
AC Immune is publicly traded on the NASDAQ stock exchange under the ticker symbol ACIU. The company is headquartered in Lausanne, Switzerland, and has additional offices in the United States and Germany.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
AC Immune uses a proprietary technology platform to develop small molecule drugs, biologics, and vaccines that target misfolded proteins. The company has a diverse pipeline of drug candidates that are currently in various stages of clinical development, including treatments for Alzheimer's disease, Parkinson's disease, and Down syndrome.
AC Immune has partnerships with several leading pharmaceutical companies, including Roche, Genentech, and Eli Lilly, to develop and commercialize its drug candidates. The company is also engaged in research collaborations with academic institutions and other biotech companies to advance its understanding of neurodegenerative diseases and develop new treatments.
AC Immune is publicly traded on the NASDAQ stock exchange under the ticker symbol ACIU. The company is headquartered in Lausanne, Switzerland, and has additional offices in the United States and Germany.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!